Hexima - Pezadeftide – a novel antifungal agent
Hexima is a pure-play biotech focused on the progression of its sole clinical asset, pezadeftide. The company aims to develop pezadeftide as a novel topical treatment for onychomycosis (fungal nail infection). Pezadeftide belongs to a novel class of molecules known as plant defensins, which are stable, soluble and possess antimicrobial activity. Following encouraging safety and efficacy results from randomised, double-blind, ascending dose-controlled Phase I/IIa trials, a Phase IIb clinical study is currently underway, with results expected in Q222.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.